Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)

被引:51
|
作者
Li, Zhuang-hua [1 ,3 ]
Qiu, Miao-zhen [1 ,2 ]
Zeng, Zhao-lei [1 ]
Luo, Hui-yan [1 ,2 ]
Wu, Wen-jing [1 ,2 ]
Wang, Feng [1 ,2 ]
Wang, Zhi-qiang [1 ,2 ]
Zhang, Dong-sheng [1 ,2 ]
Li, Yu-hong [1 ,2 ]
Xu, Rui-hua [1 ,2 ]
机构
[1] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China
[3] Dongguan Peoples Hosp, Dept Med Oncol, Dongguan 523059, Guangdong, Peoples R China
来源
关键词
CISPLATIN RESISTANCE; MULTIDRUG-RESISTANCE; PROGNOSTIC-FACTOR; EXPRESSION; OXALIPLATIN; CARBOPLATIN; CARCINOMA; LINE; DNA;
D O I
10.1186/1479-5876-10-21
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Copper export protein ATP7A is important for maintaining copper homeostasis. Recent studies have shown that copper transporters are also involved in the transport of platinum. The goal of this study was to determine the role of ATP7A in the platinum-resistance of non-small cell lung cancer (NSCLC). Methods: Sensitivities to platinums were detected by MTT assay and drug-resistance related genes were analyzed by real-time PCR and immunoblotting between DDP-sensitive A549 and the corresponding DDP-resistant cell subline (A549/DDP). ATP7A expression was evaluated by immunohistochemistry in tumor tissues of unresectable NSCLC patients who received cisplatin-basing chemotherapy. Results: The expression of ATP7A was significantly higher in A549/DDP cell subline than in A549 cells at both mRNA and protein levels. The silencing of ATP7A expression in A549/DDP by siRNA partially reversed DDP-resistance (29.62%) and increased cell apoptosis. ATP7A expression was detected in 41.6% of NSCLC patients, but not in adjacent stroma nor normal lung tissues. ATP7A-positive patients had a significantly poorer histological grade (p = 0.039) and poorer response to platinum-basing chemotherapy (p = 0.001) compared with ATP7A-negative patients. Cox's proportional hazards analysis showed that ATP7A expression was an independent prognostic factor for overall survival (p = 0.045). Conclusions: ATP7A overexpression played an important role in platinum-resistance of NSCLC, and was a negative prognostic factor of NSCLC patients treated with platinum-based chemotherapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PGRMC1 AS A PREDICTIVE MARKER FOR PLATINUM RESISTANCE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Bogush, T. A.
    Dudko, E. A.
    Nureev, M. V.
    Kamensky, A. A.
    Polotsky, B. E.
    Tjulandin, S. A.
    Davydov, M. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
  • [32] microRNA (miR) analysis as a tool for discovering platinum resistance mechanisms in non-small cell lung cancer (NSCLC)
    Bar, Jair
    Perez-Iratxeta, Carolina
    Gorn-hundermann, Ivan
    Stefanie, Reid
    Goss, Glenwood D.
    Dimitroulakos, Jim
    CANCER RESEARCH, 2011, 71
  • [33] Transformation of Non-Small Cell Lung Cancer (NSCLC) to Small Cell Lung Cancer (SCLC), Mechanism of Treatment Resistance?
    Hamedi, Z.
    Kamboj, S.
    Kumar, S.
    Jiwani, R. A.
    Sharma, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [34] Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel, SM
    Shehadeh, NJ
    Ruckdeschel, JC
    Chaplen, RA
    Belzer, K
    Wozniak, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [35] ATP7A IS A NOVEL DETERMINANT OF TOXICITY AND RESPONSE IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING PACLITAXEL AND CARBOPLATIN
    Harris, Benjamin D.
    Perera, Vidya
    Viet Phan
    Mclachlan, Andrew
    Clarke, Stephen
    Charles, Kellie
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1045 - S1045
  • [36] Utilities associated with non-small cell lung cancer (NSCLC): A community study
    Tabberer, M.
    Stamuli, E.
    Walker, M.
    Summerhayes, M.
    Lees, M.
    VALUE IN HEALTH, 2006, 9 (06) : A298 - A298
  • [37] Activin as a biomarker for platinum resistance in non-small cell lung cancer.
    Lim, Jennifer Wen Ying
    Murphy, Alexander David
    O'Toole, Sandra
    Nagrial, Adnan
    Karikios, Deme John
    Daneshvar, Dariush
    Murphy, Angela
    McCloy, Rachael
    Watkins, Neil
    Chin, Venessa T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen
    Ze-jun Lu
    Qi-fang Song
    Sa-sa Jiang
    Qi Song
    Wei Wang
    Gao-hua Zhang
    Bin Kan
    Lan-tu Gou
    Li-juan Chen
    Feng Luo
    Zhi Yong Qian
    Jin-liang Yang
    Yu Quan Wei
    BMC Cancer, 9
  • [39] Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen
    Lu, Ze-jun
    Song, Qi-fang
    Jiang, Sa-sa
    Song, Qi
    Wang, Wei
    Zhang, Gao-hua
    Kan, Bin
    Chen, Li-juan
    Yang, Jin-liang
    Luo, Feng
    Qian, Zhi Yong
    Wei, Yu Quan
    Gou, Lan-tu
    BMC CANCER, 2009, 9
  • [40] Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells
    Zheng, Mao Dong
    Wang, Nai Dong
    Li, Xiao Liang
    Yan, Juan
    Tang, Jian Hua
    Zhao, Xiu Hua
    Zhang, Zhihua
    JOURNAL OF NATURAL MEDICINES, 2018, 72 (03) : 724 - 733